The 6 most recent market catalysts affecting $CATX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair's initiation of coverage on Perspective Therapeutics (CATX) with an Outperform rating and a substantial price target of $11.45 (compared to a $2.70 closing price) is …
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 65
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating
William Blair, a reputable investment bank, has initiated coverage on Perspective Therapeutics (CATX) with an 'Outperform' rating. This event is significant because analyst coverag…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 75
Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer
Perspective Therapeutics (CATX) has entered a clinical trial collaboration with Merck (MRK) to combine its radiopharmaceutical PSV359 with Merck's Keytruda. This is a significant p…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11
BMO Capital's initiation of coverage on Perspective Therapeutics (CATX) with an 'Outperform' rating and an $11 price target is a significant positive development for the company. A…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14
Piper Sandler analyst Biren Amin maintained an 'Overweight' rating on Perspective Therapeutics (CATX) but lowered the price target from $16 to $14. This action suggests that while …
Jul 17, 2026
Corporate Catalyst
Neutral
Impact 55
Perspective Therapeutics' Updated Data On Its [212Pb]VMT-α-NET Program Accepted For Presentation At European Society Of Medical Oncology Congress 2026
Perspective Therapeutics announced that updated data on its [212Pb]VMT-α-NET program will be presented at the ESMO Congress in October 2026. This is a positive development as it si…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.